In December, when Merck revealed that Lynparza didn’t add benefits to Keytruda in certain non-small cell lung cancer (NSCLC) patients, the trial appeared to be a complete failure. Although the study itself is beyond salvaging, detailed data now raise some hope for the combination in the future.
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
AstraZeneca Shows Lynparza Combo Could Address Unmet Endometrial Cancer Need
Zydus launches anti-cancer generic drug olaparib in India
Merck halts trial after Keytruda-Lynparza combo flunks PhIII study in lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the primary analysis of the DUO-E Phase III trial showed that IMFINZI® (durvalumab) plus platinum-based chemotherapy, followed by either IMFINZI monotherapy or IMFINZI plus LYNPARZA® (olaparib), both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy alone in the overall trial population of patients with newly diagnosed advanced or recurrent endometrial cancer.
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
MISSISSAUGA, ON, July 13, 2023 /CNW/ - Health Canada has granted a Notice of Compliance with Conditions (NOC/c) for Lynparza® (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before Lynparza treatment is initiated.1
Enhanced antitumor activity was shown with the addition of the PARP inhibitor olaparib (Lynparza) to the radioligand lutetium Lu 177 vipivotide tetraxetan (Pluvicto; formerly 177Lu-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC), according to early findings from the phase 1 LuPARP study (NCT03874884).1
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA® (olaparib), IMFINZI® (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy plus bevacizumab (control arm) in newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumor BRCA mutations. Patients were treated with IMFINZI in combination with chemotherapy and bevacizumab followed by IMFINZI, LYNPARZA and bevacizumab as maintenance therapy.